Get the Stockscreener App
0.80
1.78%
-0.0145
After Hours:
.79
-0.01
-1.25%
Achilles Therapeutics Plc ADR stock is currently priced at $0.80, with a 24-hour trading volume of 187.43K.
It has seen a -1.78% decreased in the last 24 hours and a -27.27% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8114 pivot point. If it approaches the $0.7931 support level, significant changes may occur.
Achilles Therapeutics Plc ADR Stock (ACHL) Financials Data
Achilles Therapeutics Plc ADR (ACHL) Net Income 2024
ACHL net income (TTM) was -$69.67 million for the quarter ending December 31, 2023, a +2.12% increase year-over-year.
Achilles Therapeutics Plc ADR (ACHL) Cash Flow 2024
ACHL recorded a free cash flow (TTM) of -$67.05 million for the quarter ending December 31, 2022, a -0.19% decrease year-over-year.
Achilles Therapeutics Plc ADR (ACHL) Earnings per Share 2024
ACHL earnings per share (TTM) was -$1.74 for the quarter ending December 31, 2023, a +4.92% growth year-over-year.
Achilles Therapeutics Plc ADR Stock (ACHL) Latest News
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Benzinga
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
GlobeNewswire Inc.
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
About Achilles Therapeutics Plc ADR
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
COMPANY PROFILE
NameAchilles Therapeutics Plc ADR
SectorHealthcare (1194)
IndustryBiotechnology (685)
Web
Phone44 20 8154 4600
Employee234
Next earning date2024-05-08
Address245 Hammersmith Road, London, United Kingdom (W6 8PW)
0.08%
0.44%
Cap:
|
Volume (24h):